In particular, antibody-based therapies targeting CTLA-4 and the PD-1/PD-L1 checkpoint pathways have reached FDA approval because of improved patient survival; however, the majority of cancer patients do not respond to checkpoint antibodies, and in the case of melanoma have a durable complete response rate of only ~15% [1,2]. Here, CTLA4 is linked to cancer.